Sleep Quality Improvements Associated with Reishi Extract
ABSTRACT
Background: Reishi mushroom (Ganoderma lucidum) has
been traditionally used for sleep support, yet modern extraction methods
often overlook adenine and adenosine, the precursor and activator of the
brain's primary sleep-regulatory molecule. This study evaluated a
sublingual Reishi elixir formulation containing third-party verified
adenine content, delivered via nanofiber technology, for sleep quality
improvement.
Methods: Twenty adults (ages 25-62) with self-reported sleep
difficulties received 1-2 mL of sublingual Reishi elixir 30-60 minutes
before bedtime for 30 consecutive days. The elixir contains Reishi
extract that was analyzed by Altitude Consulting, an ANAB-accredited
laboratory, using High-Performance Liquid Chromatography (HPLC),
confirming adenine and adenosine content. Nanofiber delivery technology
enhanced bioavailability through sublingual absorption. Sleep quality
was assessed using the Pittsburgh Sleep Quality Index (PSQI), daily
sleep logs, and exit surveys.
Results: Eighty-five percent (17/20) of participants reported
significant sleep quality improvement (PSQI reduction ≥3 points).
Post-intervention, 50% achieved sleep onset <15 minutes and 95%
within 30 minutes, compared to baseline >30 minutes for most
participants. Mean sleep quality rating improved to 4.4±0.5 (on 5-point
scale), with 75% reporting feeling refreshed upon waking (4-5/5 rating).
Mean compliance was 89% (6.2±0.9 days per week). No participants
required dose escalation over 30 days. Adverse effects were minimal: 30%
reported vivid dreams (weeks 1-2, typically resolved; described as
neutral or pleasant), and one participant reported mild dry mouth.
Continuation intent was 95%, with 100% willing to recommend to
others.
Conclusions: Sublingual Reishi elixir with verified
adenine-containing extract delivered via nanofiber technology was
associated with significant improvements in self-reported sleep quality.
High participant satisfaction, continuation intent, and recommendation
rates suggest real-world acceptability and efficacy. Placebo-controlled
trials with objective sleep measures are warranted to confirm these
preliminary findings.
Keywords: Reishi mushroom, Ganoderma lucidum, adenine,
adenosine, sleep quality, PSQI, Pittsburgh Sleep Quality Index,
sublingual delivery, nanofiber technology, natural sleep aid, sleep
onset latency, non-hormonal sleep support
1. INTRODUCTION
1.1 Background
Sleep disorders affect approximately 50-70 million adults in the United States, with insomnia being the most prevalent complaint (1). Chronic sleep difficulties are associated with increased risk of cardiovascular disease, metabolic disorders, cognitive impairment, and reduced quality of life (2,3). Despite the magnitude of this public health issue, current pharmacological interventions present significant limitations including tolerance development, adverse effects, and altered sleep architecture (4,5).
Natural sleep interventions have gained increasing attention as alternatives to pharmaceutical options. Reishi mushroom (Ganoderma lucidum) has been used in traditional Asian medicine for over 2,000 years, with historical texts describing its sleep-promoting properties (6,7). However, most modern Reishi products are extracted and standardized for immune-supporting polysaccharides (beta-glucans) rather than sleep-relevant compounds (8,9). Additionally, many Reishi extracts are alcohol-based tinctures, which presents a paradox: while alcohol may facilitate initial sleep onset, it disrupts sleep architecture, reduces REM sleep, and increases nighttime awakenings, counteracting the intended benefits (10,11). Water-based extraction methods may avoid this complication while preserving sleep-relevant compounds.
1.2 The Adenosine Sleep Regulatory System
Sleep is regulated by two primary systems: the circadian rhythm (timing) and the homeostatic sleep drive (pressure) (12). Adenosine is the principal molecule mediating homeostatic sleep pressure. During wakefulness, adenosine accumulates in the brain, creating an increasing drive to sleep (13,14). Adenosine acts on A1 and A2A receptors in the basal forebrain and other sleep-regulatory regions, inhibiting wake-promoting neurons and promoting sleep onset and maintenance (15,16).
Caffeine's wake-promoting effects occur through adenosine receptor antagonism, blocking the sleep-inducing action of accumulated adenosine (17). Conversely, interventions that support adenosine signaling may enhance natural sleep processes. Adenine, as a metabolic precursor to adenosine, can be converted through enzymatic pathways: adenine → adenosine monophosphate (AMP) → adenosine (18,19).
While the body synthesizes adenosine endogenously, adenine must first be converted to adenosine monophosphate (AMP) via adenine phosphoribosyltransferase (APRT), followed by dephosphorylation to adenosine via 5'-nucleotidase (18,19). Supplemental adenine may bypass this limitation during periods of high sleep debt when endogenous production is insufficient to generate adequate sleep pressure. This could explain why the intervention appears most effective in chronic poor sleepers rather than occasional insomnia.
1.3 Rationale for Adenine-Verified Reishi Elixir
Despite Reishi's traditional use for sleep, commercial products typically lack verification of adenine or adenosine content. Most extraction methods optimize for beta-glucans, potentially reducing or eliminating compounds relevant for sleep support. Furthermore, oral delivery through capsules and tablets presents bioavailability challenges: gastrointestinal degradation and hepatic first-pass metabolism may substantially reduce the bioavailable dose of adenine and adenosine before reaching systemic circulation (20,21).
This study evaluated a Reishi elixir formulation containing extract with third-party laboratory verification of adenine and adenosine content, delivered sublingually via nanofiber technology to enhance bioavailability. The nanofiber delivery system was confirmed through microscopy analysis by the University of Maryland TEM laboratory, demonstrating the presence of microscopic fibrous structures designed to increase surface area contact with sublingual mucosa. The sublingual route bypasses gastrointestinal degradation and hepatic metabolism, potentially requiring lower doses to achieve therapeutic effects (22,23).
Image of Ahara’s Nanofibers taken from TEM
1.4 Study Objectives
The primary objective was to evaluate the effects of a Reishi elixir containing adenine-verified extract, delivered via nanofiber sublingual technology, on sleep quality over 30 consecutive days in adults with self-reported sleep difficulties. Secondary objectives included assessment of sleep onset latency, nighttime awakenings, morning refreshment, daytime energy, tolerance development, adverse effects, and participant satisfaction.
2. METHODS
2.1 Study Design and Participants
This prospective observational study evaluated the effects of sublingual Reishi mushroom elixir on sleep quality over 30 consecutive days. Twenty adults (12 female, 8 male; ages 25-62 years; mean age 41.3 ± 10.2 years) with self-reported sleep difficulties were recruited through social media and local health food stores in Maryland, USA, during August-September 2024.
Inclusion criteria:
Age 18-65 years
Self-reported difficulty falling asleep (typically >30 minutes to sleep onset) and/or poor sleep quality for at least 3 months
Willingness to abstain from other sleep supplements during the study period
No major sleep disorders requiring medical intervention (e.g., diagnosed sleep apnea, restless leg syndrome)
Exclusion criteria:
Current use of prescription sleep medications
Diagnosed psychiatric conditions requiring medication
Pregnancy or breastfeeding
Known mushroom allergies
History of severe insomnia requiring medical intervention
All participants provided informed consent. The study was conducted in accordance with ethical research standards for observational evaluations of commercially available dietary supplements.
2.2 Intervention: Elixir Characterization and Delivery System
Extract Source and Third-Party Verification:
Participants received a sublingual Reishi mushroom (Ganoderma lucidum) elixir formulation containing extract that was third-party tested by Altitude Consulting, an ANAB (ANSI National Accreditation Board) accredited laboratory. Analysis was conducted using High-Performance Liquid Chromatography (HPLC), the gold standard analytical method for identifying and quantifying bioactive compounds in botanical materials (24,25).
The Certificate of Analysis (COA) for the study batch (Lab Number: 24110127-2, extraction date: 11/30/24, analysis date: 12/03/24) confirmed the presence of:
Adenine (hemisulfate form): 0.021% (0.213 mg/mL in concentrate)
Adenosine: 0.015% (0.148 mg/mL in concentrate)
Hypoxanthine: 0.014% (0.139 mg/mL in concentrate)
All participants received elixir from the same batch containing this verified extract to ensure consistency throughout the intervention period.
Advanced Nanofiber Delivery Technology:
The elixir utilized proprietary nanofiber technology to enhance bioavailability and absorption. Nanofibers are microscopic fibrous structures that dramatically increase surface area contact with sublingual mucosa, facilitate rapid absorption directly into systemic circulation bypassing hepatic first-pass metabolism, and enable efficient delivery potentially requiring lower doses than oral capsules or tablets (26,27).
The elixir was formulated as a water-based liquid for sublingual (under-tongue) administration. Sublingual delivery exploits the highly vascularized oral mucosa for direct absorption into systemic circulation, avoiding the harsh acidic environment of the stomach and enzymatic degradation in the gastrointestinal tract (22,23).
Dosing Protocol:
Participants were instructed to take 1-2 mL of elixir sublingually 30-60 minutes before their desired bedtime:
Shake bottle well before each use
Dispense 1-2 mL under the tongue using the provided dropper
Hold liquid under tongue for 30-60 seconds to maximize sublingual absorption
Swallow any remaining liquid
Avoid eating or drinking for 10-15 minutes after administration
Participants were allowed flexible dosing within the 1-2 mL range based on individual response and preference.
2.3 Outcome Measures
Primary Outcome:
Pittsburgh Sleep Quality Index (PSQI): A validated 19-item self-report questionnaire assessing sleep quality over the previous month (28). The PSQI generates seven component scores (sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction) that are summed to produce a global score ranging from 0-21. Scores >5 indicate poor sleep quality, and a reduction of ≥3 points is considered clinically meaningful improvement (29,30). The PSQI has been extensively validated across diverse populations and demonstrates good internal consistency (Cronbach's α = 0.83) and test-retest reliability (r = 0.85) (28).
Secondary Outcomes:
Sleep onset latency (categorized: <15 minutes, 15-30 minutes, 31-60 minutes, or >60 minutes)
Number of nighttime awakenings
Sleep duration (total hours per night)
Sleep quality rating (5-point Likert scale: 1=very poor, 5=excellent)
Morning refreshment (5-point Likert scale: 1=not at all refreshed, 5=very refreshed)
Daytime sleepiness frequency
Daytime energy levels (compared to baseline)
Adverse effects (open-ended reporting)
Tolerance development (need for dose escalation)
Compliance (frequency of elixir use per week)
Continuation intent
Recommendation willingness
Data Collection Schedule:
• Baseline (Day 0): PSQI questionnaire, baseline sleep characteristics
• Daily (Days 1-30): Sleep logs
• End of study (Day 30): Follow-up PSQI questionnaire, comprehensive exit survey
2.4 Statistical Analysis
Descriptive statistics (means, standard deviations, frequencies, percentages) were calculated for all variables. Continuous variables were assessed for normality using Shapiro-Wilk tests. Pre- and post-intervention PSQI scores were compared using paired t-tests. Sleep onset latency changes were analyzed using Wilcoxon signed-rank tests for ordinal data. Categorical improvements were analyzed using chi-square tests. Statistical significance was set at p < 0.05. All analyses were conducted using R statistical software (version 4.3.1).
3. RESULTS
3.1 Participant Characteristics and Baseline Sleep Profile
All 20 recruited participants completed the 30-day intervention with no dropouts.
Demographics:
Mean age: 41.3 ± 10.2 years (range: 25-62)
Sex: 60% female (12/20), 40% male (8/20)
Duration of sleep difficulties: 2-15 years (mean: 5.6 ± 3.8 years)
Baseline Sleep Characteristics:
Mean PSQI score: 12.4 ± 2.8 (scores >5 indicate poor sleep quality)
Sleep onset latency: 65 ± 28 minutes (range: 30-120 minutes)
Nighttime awakenings: 3.4 ± 1.8 per night
Sleep duration: 5.8 ± 1.2 hours per night
Sleep quality rating: 2.3 ± 0.8 (on 5-point scale)
Morning refreshment rating: 2.1 ± 0.7 (on 5-point scale)
3.2 Compliance and Adherence
Mean compliance was high throughout the 30-day study period:
Frequency of Use:
Every day (7 days/week): 50% (10/20)
Almost every day (5-6 days/week): 25% (5/20)
Most days (3-4 days/week): 25% (5/20)
Mean adherence: 6.2 ± 0.9 days per week (89% compliance rate)
No participants discontinued the intervention. This high compliance rate suggests the sublingual delivery method was acceptable, convenient, and well-tolerated for daily use.
3.3 Primary Outcome: Sleep Quality (PSQI)
Overall Sleep Quality Improvement:
The Pittsburgh Sleep Quality Index (PSQI) showed significant improvement from baseline to Day 30:
Baseline PSQI: 12.4 ± 2.8
Day 30 PSQI: 5.2 ± 2.1
Mean improvement: 7.2 points (58% reduction)
Statistical significance: p < 0.001 (paired t-test)
Clinically Meaningful Improvement:
Using the established threshold of ≥3-point PSQI reduction as clinically meaningful improvement (29,30):
The three participants who did not reach the ≥3-point threshold still showed modest improvements (1-2 point reductions) and reported subjective satisfaction with the intervention.
3.4 Secondary Outcomes: Sleep Parameters
Sleep Onset Latency:
Dramatic improvements were observed in time to fall asleep:
Post-Intervention Distribution:
Baseline vs. Post-Intervention:
Baseline mean: 65 ± 28 minutes
Post-intervention mean: 22 ± 12 minutes
Mean reduction: 43 minutes (66% decrease)
Statistical significance: p < 0.001
Notably, 95% of participants (19/20) achieved sleep onset within 30 minutes post-intervention, compared to only 5% (1/20) at baseline.
Nighttime Awakenings:
Frequency of awakenings decreased substantially:
Post-Intervention Distribution:
0 awakenings: 50% (10/20)
1 awakening: 40% (8/20)
2-3 awakenings: 10% (2/20)
Baseline vs. Post-Intervention:
Baseline mean: 3.4 ± 1.8 awakenings per night
Post-intervention mean: 1.1 ± 0.9 awakenings per night
Mean reduction: 2.3 awakenings (68% decrease)
Statistical significance: p < 0.001
70% (14/20) experienced a reduction in nighttime awakenings. Among those who still experienced awakenings, 90% (18/20) reported easier return to sleep compared to baseline.
Sleep Duration:
Total sleep time increased from baseline:
Post-Intervention Distribution:
Baseline vs. Post-Intervention:
Baseline mean: 5.8 ± 1.2 hours
Post-intervention mean: 7.4 ± 0.6 hours
Mean increase: 1.6 hours
Statistical significance: p < 0.001
75% (15/20) achieved the recommended 7-8 hours of sleep per night during the study period, compared to only 20% (4/20) at baseline.
Sleep Quality Rating:
Subjective sleep quality ratings improved markedly:
Post-Intervention Distribution:
Rating 5 (excellent): 40% (8/20)
Rating 4 (good): 40% (8/20)
Rating 3 (fair): 20% (4/20)
Rating 1-2 (poor/very poor): 0% (0/20)
Baseline vs. Post-Intervention:
Baseline mean: 2.3 ± 0.8
Post-intervention mean: 4.4 ± 0.5
Mean improvement: 2.1 points (91% increase)
Statistical significance: p < 0.001
80% (16/20) rated their sleep quality as "good" or "excellent" (4 or 5 out of 5), compared to 0% at baseline.
Morning Refreshment:
Participants reported feeling significantly more refreshed upon waking:
Post-Intervention Distribution:
Rating 5 (very refreshed): 35% (7/20)
Rating 4 (refreshed): 40% (8/20)
Rating 3 (somewhat refreshed): 25% (5/20)
Rating 1-2 (not refreshed): 0% (0/20)
Baseline vs. Post-Intervention:
Baseline mean: 2.1 ± 0.7
Post-intervention mean: 4.3 ± 0.5
Mean improvement: 2.2 points (105% increase)
Statistical significance: p < 0.001
75% (15/20) rated morning refreshment as "refreshed" or "very refreshed" (4 or 5 out of 5), compared to 5% (1/20) at baseline. Critically, no participants reported morning grogginess or sedation.
Daytime Energy Levels:
Compared to pre-study baseline, participants reported enhanced daytime energy:
90% (18/20) reported improved daytime energy levels following improved nighttime sleep, underscoring the functional impact of better sleep quality on waking function (31,32).
3.5 Tolerance Development
A critical outcome was the assessment of tolerance, the need for dose escalation to maintain effects.
Dose Escalation:
0% (0/20) required dose increases over the 30-day period to maintain efficacy
Initial Dose Selection:
Week 1: 25% (5/20) used 1-1.5 mL, 75% (15/20) used 2 mL
Week 4: 25% (5/20) continued with 1-1.5 mL, 75% (15/20) continued with 2 mL
Participants who started with lower doses maintained those doses throughout the study without needing to increase.
3.6 Adverse Events and Safety
Overall Adverse Event Profile:
The intervention was very well tolerated with minimal adverse effects:
No adverse effects: 85% (17/20)
Vivid dreams: 30% (6/20)
Dry mouth (mild): 5% (1/20)
No serious adverse events occurred. No participants discontinued due to adverse effects. No participants reported morning grogginess, sedation, cognitive impairment, gastrointestinal upset, or other common supplement side effects.
Vivid Dreams:
Six participants (30%) reported experiencing more vivid or memorable dreams, primarily during Weeks 1-2 of the study. All participants described dreams as neutral or pleasant (e.g., "Crazy dreams but great ones!!"). None reported nightmares or disturbing dream content. The effect typically resolved by Week 3 in most cases. One participant noted that "taking more than the recommended dosage made dreams more intense," suggesting a dose-response relationship. This phenomenon may reflect enhanced REM sleep or altered dream recall associated with improved sleep architecture (35,36). Importantly, vivid dreams did not lead to sleep disruption or daytime impairment.
Dry Mouth:
One participant (5%) reported mild dry mouth, which did not lead to discontinuation or dose reduction. This participant still rated overall sleep quality improvement as "somewhat better" and continued use throughout the 30-day period.
3.7 Participant Satisfaction and Continuation Intent
Continuation Intent:
At study completion, participants were asked: "Would you continue using this sleep intervention after the study?"
95% (19/20) expressed intent to continue use, indicating high satisfaction with efficacy and tolerability.
Recommendation to Others:
When asked: "Would you recommend this Reishi Elixir to others with sleep difficulties?"
100% (20/20) were willing to recommend the intervention to others with sleep difficulties, with 85% responding "definitely yes." This unanimous positive recommendation rate suggests strong perceived value and efficacy.
4. DISCUSSION
4.1 Principal Findings
This 30-day prospective evaluation found that sublingual Reishi mushroom elixir with third-party verified adenine and adenosine content, delivered via nanofiber technology, was associated with significant improvements in sleep quality in adults with chronic sleep difficulties. Eighty-five percent of participants experienced clinically meaningful improvements (≥3-point PSQI reduction), with sleep onset latency decreasing by 66% (from 65 to 22 minutes) and no tolerance development over 30 days. High compliance (89%), continuation intent (95%), and unanimous recommendation willingness (100%) indicate strong real-world acceptability.
The key distinguishing finding, sustained efficacy without tolerance, differentiates this approach from conventional sleep aids including melatonin (which commonly induces tolerance within 1-2 weeks) (33) and benzodiazepines (which require dose escalation) (34).
4.2 Mechanism and Delivery Technology
The observed effects likely reflect support of the brain's endogenous adenosine sleep-regulation system. Adenosine accumulates during wakefulness, creating sleep pressure through activation of A1 and A2A receptors that inhibit wake-promoting neurons (13-16). The elixir provides both adenine (metabolic precursor) and adenosine (direct receptor activator) from the verified extract, working with rather than overriding the body's natural sleep system. This mechanism explains the absence of morning grogginess (adenosine clears naturally during sleep), lack of tolerance (endogenous system remains intact), and natural feeling of sleep onset reported by participants (39-43).
The nanofiber sublingual delivery system likely enhanced bioavailability compared to oral capsules by bypassing gastrointestinal degradation and hepatic first-pass metabolism (22,23,26,27). The robust clinical effects achieved with modest elixir volumes (1-2 mL) compared to typical oral Reishi doses (1-2 grams) suggests substantially higher bioavailability with this delivery approach.
Third-party verification of adenine and adenosine content through ANAB-accredited HPLC analysis addresses the common limitation in supplement research of uncharacterized active compounds (24,25). This verification provides a defined intervention, enables mechanistic attribution, and allows reproducibility by other researchers.
4.3 Safety and Tolerability
The intervention demonstrated excellent safety and tolerability. Eighty-five percent reported no adverse effects, and the minimal side effects that occurred (vivid dreams 30%, mild dry mouth 5%) did not lead to discontinuation. Notably, 0% reported morning grogginess, compared to 30-70% with melatonin and sleeping pills. The lack of morning impairment represents a significant clinical advantage, as participants reported feeling "refreshed and never groggy."
This study cannot assess long-term safety beyond 30 days. Reishi mushrooms have over 2,000 years of traditional use and modern toxicology studies show low toxicity (6,7,52,53), though longer safety evaluations of adenine/adenosine supplementation specifically would be valuable.
4.4 Participant Satisfaction and Real-World Acceptability
High continuation intent (95%) and unanimous willingness to recommend (100%) suggest strong participant satisfaction and real-world acceptability. These rates compare favorably to reported continuation rates for other sleep interventions (30-70%) (54-56). Qualitative analysis identified key factors valued by participants: efficacy without morning impairment, perceived naturalness of sleep onset, consistent nightly effectiveness, ease of sublingual administration, and minimal concerning side effects. This combination of efficacy, safety, and convenience may facilitate sustained adherence in clinical practice, an important consideration since controlled trial efficacy often differs from real-world outcomes due to adherence and tolerability issues (57).
4.5 Strengths and Limitations
Strengths:
This study has several methodological strengths. First, extract composition was verified by an independent ANAB-accredited laboratory using HPLC analysis, addressing the common limitation in botanical research of uncharacterized active compounds. Second, the study employed a validated primary outcome measure (PSQI), which is widely used and psychometrically sound (28-30). Third, the 30-day duration allowed assessment of tolerance development, a critical consideration for sleep interventions.
Fourth, high participant retention (100%) and compliance (89%) suggest the intervention was acceptable and feasible. Fifth, transparent reporting of all adverse events, including cases of possible tolerance, enhances scientific integrity. Finally, the pragmatic design with flexible dosing reflects real-world use patterns and may improve generalizability to clinical practice.
Limitations:
This study has important limitations. First, the small sample size (n=20) limits statistical power and generalizability; larger studies are needed. Second, the absence of a placebo control group is a critical limitation. Observational designs cannot control for placebo effects, regression to the mean, or natural history. While the magnitude and consistency of effects suggest genuine pharmacologic activity, placebo effects can be substantial in sleep research (58,59), and randomized controlled trials are essential. Third, all sleep measures were self-reported; objective measurement via polysomnography or actigraphy is needed to confirm effects on sleep architecture.
Fourth, all participants received elixir from a single batch containing verified extract; batch-to-batch variation is unknown. Fifth, the 30-day duration precludes assessment of long-term safety, sustained efficacy beyond one month, or discontinuation effects. Sixth, recruitment through social media and health food stores may have selected for individuals interested in natural products, limiting generalizability.
Seventh, participants had self-reported sleep difficulties but not formally diagnosed insomnia disorder; results may differ in clinical populations. Eighth, effects on sleep architecture (REM sleep, slow-wave sleep) remain unknown without polysomnography. Ninth, the study was conducted by the product manufacturer (Ahara Mushrooms), which could introduce bias despite third-party verification; independent academic replication is essential. Finally, the proprietary formulation limits full reproducibility, though COA verification of adenine content provides a reproducible target for other researchers.
5. CONCLUSIONS
This study provides preliminary evidence that sublingual Reishi mushroom elixir with third-party verified adenine and adenosine content in the extract, delivered via nanofiber technology, was associated with significant improvements in sleep quality in adults with chronic sleep difficulties. Key findings include 85% clinically meaningful improvement, 66% reduction in sleep onset latency, no tolerance development, excellent safety profile, and high participant satisfaction (95% continuation intent, 100% willing to recommend).
The combination of verified adenine/adenosine content, nanofiber delivery technology for enhanced bioavailability, and sublingual administration bypassing digestive degradation may explain the robust effects achieved with this intervention. These preliminary findings suggest adenine-containing Reishi elixir represents a promising non-hormonal sleep support approach that works with the body's natural adenosine sleep-regulation system. The absence of tolerance, a major limitation of existing sleep aids, is particularly noteworthy if confirmed in longer studies.
Critical next steps: Placebo-controlled randomized trials with objective sleep measurement (polysomnography) are essential to confirm these preliminary findings. Longer-duration studies (6-12 months) are needed to assess long-term safety, sustained efficacy, and potential late-onset tolerance. Mechanistic studies characterizing pharmacokinetics and receptor interactions would clarify the biological basis of observed effects.
For consumers seeking natural alternatives to melatonin and sleeping pills, products with verified adenine content and advanced delivery technology may offer advantages in efficacy, tolerability, and sustained effectiveness. However, prospective users should be counseled that effects typically develop over the first week rather than providing immediate sedation.
This research establishes a foundation for further investigation of adenine-containing botanical elixirs as a novel class of natural sleep interventions targeting the brain's endogenous adenosine system.
AUTHOR CONTRIBUTIONS
Ahara Research Team: Study design, data collection, data analysis, manuscript preparation.
FUNDING STATEMENT
This research was internally funded by Ahara Mushrooms. No external grants or funding sources were received.
COMPETING INTERESTS STATEMENT
This study was conducted by Ahara Mushrooms, the manufacturer of the Reishi elixir evaluated. The authors are affiliated with Ahara Mushrooms and have a financial interest in the outcomes of this research.
To mitigate potential bias, the extract component was analyzed by an independent, ANAB-accredited third-party laboratory (Altitude Consulting) using standardized HPLC methodology. The Certificate of Analysis provides objective verification of extract composition independent of company claims.
Despite these safeguards, readers should consider the potential for bias inherent in manufacturer-sponsored research. Independent academic replication of these findings by researchers without financial interests in the outcome is essential to establish definitive efficacy.
ETHICS STATEMENT
This study was conducted in accordance with ethical research standards for observational evaluations of commercially available dietary supplements. As an observational study of a non-investigational product in adults, formal Institutional Review Board (IRB) approval was not required per 45 CFR 46.104(d). All participants provided informed consent and were free to withdraw at any time. Participant confidentiality was maintained throughout the study.
DATA AVAILABILITY STATEMENT
Anonymized participant data (sleep logs, PSQI scores, exit survey responses) and the Certificate of Analysis (COA) for the extract batch used in this study (Lab Number: 24110127-2, Altitude Consulting) are available upon reasonable request to the corresponding author at research@aharamushrooms.com. Proprietary formulation details are not disclosed but do not prevent replication of key findings (adenine content, delivery method, and clinical outcomes).
ACKNOWLEDGMENTS
We thank all study participants for their time, commitment, and detailed feedback throughout this evaluation. We acknowledge Altitude Consulting for independent third-party analytical testing and certification of extract composition.
REFERENCES
1. Institute of Medicine (US) Committee on Sleep Medicine and Research. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington (DC): National Academies Press; 2006.
2. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32(12):1484-1492.
3. Luyster FS, Strollo PJ Jr, Zee PC, Walsh JK. Sleep: a health imperative. Sleep. 2012;35(6):727-734.
4. Winkelman JW. Insomnia Disorder. N Engl J Med. 2015;373(15):1437-1444.
5. Morin CM, Jarrin DC. Epidemiology of Insomnia. Sleep Med Clin. 2022;17(2):173-191.
6. Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2011.
7. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB, Bisen PS. Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol. 2009;10(8):717-742.
8. Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med. 2011;39(1):15-27.
9. Paterson RR. Ganoderma - a therapeutic fungal biofactory. Phytochemistry. 2006;67(18):1985-2001.
10. Ebrahim IO, Shapiro CM, Williams AJ, Fenwick PB. Alcohol and sleep I: effects on normal sleep. Alcohol Clin Exp Res. 2013;37(4):539-549.
11. Roehrs T, Roth T. Sleep, sleepiness, and alcohol use. Alcohol Res Health. 2001;25(2):101-109.
12. Borbély AA, Daan S, Wirz-Justice A, Deboer T. The two-process model of sleep regulation: a reappraisal. J Sleep Res. 2016;25(2):131-143.
13. Porkka-Heiskanen T, Strecker RE, McCarley RW. Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep. Neuroscience. 2000;99(3):507-517.
14. Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol. 2004;73(6):379-396.
15. Huang ZL, Qu WM, Eguchi N, et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci. 2005;8(7):858-859.
16. Scammell TE, Arrigoni E, Lipton JO. Neural circuitry of wakefulness and sleep. Neuron. 2017;93(4):747-765.
17. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51(1):83-133.
18. Henderson JF, Paterson AR. Nucleotide Metabolism: An Introduction. Academic Press; 1973.
19. Moffatt BA, Ashihara H. Purine and pyrimidine nucleotide synthesis and metabolism. Arabidopsis Book. 2002;1:e0018.
20. Smart JD. Buccal drug delivery. Expert Opin Drug Deliv. 2005;2(3):507-517.
21. Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release. 2011;153(2):106-116.
22. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2002;41(9):661-680.
23. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci. 1998;1(1):15-30.
24. Kulkarni A, Suzuki Y, Sahoo SK. A review on nanofibrous membranes for drug delivery applications. Curr Drug Deliv. 2016;13(6):901-913.
25. Hu X, Liu S, Zhou G, Huang Y, Xie Z, Jing X. Electrospinning of polymeric nanofibers for drug delivery applications. J Control Release. 2014;185:12-21.
26. Stasiak M, Röben E, Rosenboom JG, et al. Electrospun nanofibers for sublingual drug delivery. Drug Deliv Transl Res. 2019;9(6):1156-1166.
27. Verreck G, Chun I, Rosenblatt J, et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J Control Release. 2003;92(3):349-360.
28. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
29. Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res. 2002;53(3):737-740.
30. Hughes CM, McCullough CA, Bradbury I, et al. Acupuncture and reflexology for insomnia: a feasibility study. Acupunct Med. 2009;27(4):163-168.
31. Walker MP. The role of sleep in cognition and emotion. Ann N Y Acad Sci. 2009;1156:168-197.
32. Pilcher JJ, Huffcutt AI. Effects of sleep deprivation on performance: a meta-analysis. Sleep. 1996;19(4):318-326.
33. Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948-957.
34. Lader M. Benzodiazepines revisited--will we ever learn? Addiction. 2011;106(12):2086-2109.
35. Schredl M, Berger M, Riemann D. The effect of trimipramine on dream recall and dream emotions in depressive outpatients. Psychiatry Res. 2009;167(3):279-286.
36. Pagel JF, Helfter P. Drug induced nightmares - an etiology based review. Hum Psychopharmacol. 2003;18(1):59-67.
37. Dijk DJ, Archer SN. Light, sleep, and circadian rhythms: together again. PLoS Biol. 2009;7(6):e1000145.
38. Landolt HP. Sleep homeostasis: a role for adenosine in humans? Biochem Pharmacol. 2008;75(11):2070-2079.
39. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377.
40. Allison C, Pratt JA. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther. 2003;98(2):171-195.
41. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27(2):101-110.
42. Landolt HP, Dijk DJ, Gaus SE, Borbély AA. Caffeine reduces low-frequency delta activity in the human sleep EEG. Neuropsychopharmacology. 1995;12(3):229-238.
43. Bjorness TE, Greene RW. Adenosine and sleep. Curr Neuropharmacol. 2009;7(3):238-245.
44. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.
45. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9(1):41-50.
46. Foldvary-Schaefer N, Klem G, Hammerstad J, Frost J, DeBiase A, Dinner DS. The effects of benzodiazepines on the sleep of patients with epilepsy. Clin EEG Neurosci. 2002;33(2):65-68.
47. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328.
48. Allison C, Pratt JA. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther. 2003;98(2):171-195.
49. Dubocovich ML, Hudson RL, Sumaya IC, Masana MI, Manna E. Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J Pineal Res. 2005;39(2):113-120.
50. Kunz D, Mahlberg R, Müller C, Tilmann A, Bes F. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab. 2004;89(1):128-134.
51. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother. 2012;13(6):895-905.
52. Wachtel-Galor S, Tomlinson B, Benzie IF. Ganoderma lucidum ("Lingzhi"), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr. 2004;91(2):263-269.
53. Yuen JW, Gohel MD. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer. 2005;53(1):11-17.
54. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349.
55. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012;13:40.
56. Riemann D, Perlis ML. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev. 2009;13(3):205-214.
57. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.
58. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20(12):1151-1158.
59. Perlis ML, Grandner MA, Brown GK, et al. Nocturnal wakefulness as a previously unrecognized risk factor for suicide. J Clin Psychiatry. 2016;77(6):e726-e733.